---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-301052"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2026-07-10T21:29:46+00:00"
generated_at: "2026-07-10T21:32:08.884121+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma raises $50M in private placement led by Cormorant and Columbia Threadneedle

## Summary
- Gross proceeds of $50M from sale of 1,418,071 shares at $33.21/share and pre-funded warrants for 87,500 shares at $33.209.
- Private placement led by Cormorant Asset Management and Columbia Threadneedle Investments; expected to close July 13, 2026.
- Net proceeds to fund clinical development and general corporate purposes; CEO cites upcoming Phase 2 CSU data from Ascendant Health expected by Q3 2026.
- Board granted 1,064,492 RSUs to employees and executives, including 655,074 RSUs to CEO Shao-Lee Lin, with time and performance-based vesting.

## SEC filing metadata
- accession: 0001193125-26-301052
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2026-07-10T21:29:46+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000119312526301052/0001193125-26-301052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000119312526301052/d123955d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-301052
- JSON: https://secwatch.observer/filing/0001193125-26-301052.json
- Plain text: https://secwatch.observer/filing/0001193125-26-301052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.